title: CD 30-positive transformed follicular lymphoma: two case reports and literature review.
abstract: OBJECTIVE
  Here we report two cases of follicular lymphoma that transformed to CD30 positive diffuse large B cell lymphoma and review the literature on this topic.
  
  
  RESULTS
  The first case represents an example of early transformation of conventional low-grade follicular lymphoma to CD30-positive large B cell lymphoma. Immunoglobulin (Ig)H and cytogenetic identity was demonstrated between both components. High-dose and auto-stem cell transplant (SCT) was applied and complete response was achieved. The second case represents an example of d'emblee transformation of intrafollicular neoplasia to CD30-positive large B cell lymphoma. Immunoglobulin K deleting element (IgKde) and cytogenetic identity between both phases was demonstrated. The patient was in partial response after four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).
  
  
  CONCLUSIONS
  CD30 expression was found to be associated in these cases to the transformation event and could be considered a therapeutic target to add to conventional immunochemotherapeutic regimens, even in combination with auto-SCT. We suggest looking for CD30 expression in transformed follicular lymphoma cases.
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.affiliation: Pathology and Hematology Departments, ICO, Hospital Universitari de Bellvitge, Barcelona, Spain.
authors.forename: Fina
authors.initials: F
authors.lastname: Climent
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: González de Villambrosía
authors.affiliation: Pathology and Hematology Departments, ICO, Hospital Universitari de Bellvitge, Barcelona, Spain.
authors.forename: Eva M
authors.initials: EM
authors.lastname: González Barca
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Batlle
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Insunza
authors.affiliation: Pathology and Hematology Departments, ICO, Hospital Universitari de Bellvitge, Barcelona, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Pané-Foix
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Colorado
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Martin-Sánchez
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Carlos Richard
authors.initials: CR
authors.lastname: Espiga
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.affiliation: Pathology and Hematology Departments, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D017730:Ki-1 Antigen; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: CD30-positive secondary diffuse large B cell lymphoma (DLBCL); FL transformation; intrafollicular neoplasia